![]() ![]() ![]() But management indicated that in order to preserve cash, they will focus on the development of existing products in their existing subsidiaries, rather than discovering new compounds, which is reasonable as the subsidiaries already have plenty of useful compounds to bring to market (in fact, some of them have already been introduced to the market).īefore we describe the company’s different subsidiaries, we have to draw attention to the fact that Evogene’s Ag-Seed division is still part of Evogene’s business. GeneRator AI for the identification and development of genetic elements. MicroBoost AI for the identification and development of new microbial candidates.ĬhemPass AI for the identification and development of new small molecules. The CPB platform has three engines, each tailored for a specific domain ( see graphic): We believe that the uniqueness of our computational prediction approach stems from our ability to successfully address multiple product attributes at the beginning of the discovery process, and during the optimization phase. This platform is the outcome of over a decade long multidisciplinary effort to integrate scientific concepts with big data and advanced computational analytics in order to develop predictions of potential product candidates that later undergo experimental validation and optimization toward commercialization. The CPB platform uses big data and machine learning and is greatly helped by the twin data and computational processing revolutions (20-F): To revolutionize the product discovery and development approach in life science industries by decoding the biological world using computational biology The mission of the CPB platform is ( 20-F): At present, the company has five subsidiaries: Successful product candidates are given their own subsidiary for further development and commercialization and they can also attract partners which help with capital needs and put a valuation on the subsidiary. Other competitors include Ginkgo Networks ( DNA), Exscientia ( EXAI), and Relay Therapeutics ( RLAY) Some of the products have already reached the commercial stage. ![]() ![]() Unlike competitors like Schödinger ( SDGR), Evogene mainly develops new compounds for its own development (through five subsidiaries and one division), rather than third parties even if it does have quite a number of partnerships and some income from IP. There is risk, but it’s well spread among five subsidiaries and one division, investors only need one of these to succeed to de-risk their investment at these levels.Įvogene ( EVGN) has a proprietary CPB (Computational Predictive Biology) platform in order to greatly improve the chances of successful product discovery and speed up product development in life science industries through the use of big data and AI. The market cap ($27M) is a fraction of the potential with many of its subsidiaries likely exceeding that on an individual basis. The company has no debt and has enough cash to last into next year with multiple additional sources of funding likely materializing at the subsidiary level well before that. ![]()
0 Comments
Leave a Reply. |